Associate Professor Nicholas Wilcken

Associate Professor
NHMRC Clinical Trials Centre, Central Clinical School

C24 - Westmead Hospital
The University of Sydney
NSW 2006 Australia

T: 9845 5200
F: 9845 6391
E:

Biographical details

Medical studies at UNSW, general medical training at Prince of Wales Hospital, oncology training at Royal Prince Alfred, PhD at the Garvan Institute. [More...]

Research interests

Breast cancer treatment, clinical trials, systematic review, evidence based clinical practice guidelines.

Current national competitive grants*

2012

A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study)
Gurney H, Balleine R, Wilcken N, Liddle C
NHMRC Project Grants ($329,901 over 3 years)

* Grants administered through the University of Sydney

Publications

2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

2014

   
  • Wilcken, N., Zdenkowski, N., White, M., Snyder, R., Pittman, K., Mainwaring, P., Green, M., Francis, P., De Boer, R., Colosimo, M., Chua, S., Chirgwin, J., Beith, J., Bell, R. (2014), Systemic treatment of HER2-positive metastatic breast cancer: A systematic review. Asia-Pacific Journal of Clinical Oncology. 10(Suppl S4), 1-14. [Abstract]
  • De Boer, R., Beith, J., Chirgwin, J., Chua, S., Colosimo, M., Francis, P., Green, M., Pittman, K., White, M., Wilcken, N., Zdenkowski, N., Bell, R. (2014), Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives. Asia-Pacific Journal of Clinical Oncology. 10(Suppl S4), 15-25. [Abstract]
  • McCarthy, N., Boyle, F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P., Chirgwin, J., Abdi, E., Gebski, V., Veillard, A., Zannino, D., Wilcken, N., Reaby, L., Lindsay, D., Badger, H., Forbes, J. (2014), Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). Breast. 23(2), 142-151. [Abstract]

2013

   
  • Dear, R., McGeechan, K., Jenkins, M., Barratt, A., Tattersall, M., Wilcken, N. (2013), Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews. 12, CD008792. [Abstract]
  • Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2013), Post-operative radiotherapy for ductal carcinoma in situ of the breast. The Cochrane Database of Systematic Reviews. 11, CD000563. [Abstract]
  • Cass-Verco, J., Mason, C., Wilcken, N. (2013), Antidepressants and tamoxifen: interaction concerns. Australasian Psychiatry. , 508-509. [Abstract]
  • Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Jefford, M., Glare, P., Stockler, M. (2013), The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology. 31(28), 3565-3571. [Abstract]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013), Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine. 11(1), 189. [Abstract]

2012

   
  • Wilcken, N. (2012), First story - MJA Dr Eric Dark Creative Writing Prize. The Medical Journal of Australia. 197(9), 526. [Abstract]
  • Balleine, R., Wilcken, N. (2012), High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy. Molecular Diagnosis & Therapy. 16(4), 235-240. [Abstract]
  • Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012), Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia. 196(11), 688-692. [Abstract]
  • Cameron, B., Bennett, B., Li, H., Boyle, F., Desouza, P., Wilcken, N., Friedlander, M., Goldstein, D., Lloyd, A. (2012), Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology. 23(11), 2890-2895. [Abstract]
  • Stockler, M., Wilcken, N. (2012), Why is management of cancer pain still a problem?. Journal of Clinical Oncology. 30, 1907-1908. [Abstract]
  • McCarthy, N., Mitchell, G., Bilous, M., Wilcken, N., Lindeman, G. (2012), Triple-negative breast cancer: making the most of a misnomer. Asia-Pacific Journal of Clinical Oncology. 8(2), 145-155. [Abstract]
  • Goldstein, D., Bennett, B., Webber, K., Boyle, F., de Souza, P., Wilcken, N., Scott, E., Toppler, R., Murie, P., O'Malley, L., McCourt, J., Friedlander, M., Hickie, I., Lloyd, A. (2012), Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. Journal of Clinical Oncology. 30(15), 1805-1812. [Abstract]
  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., Wong, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012), Decision making in older patients with advanced cancer: does doctor know best?. Medical Journal of Australia. 196(1), 35-36. [Abstract]

2011

   
  • Wilcken, N. (2011), Nine letters. The Lancet Oncology. 12(13), 1193-1194. [Abstract]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Gainford, M., Fong, A., Paksec, L., Sourjina, T., Zannino, D., Gebski, V., Simes, R., Forbes, J., Coates, A. (2011), Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology. 29(34), 4498-4504. [Abstract]
  • Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., Decensi, A., Bruzzi, P. (2011), Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(16), 2144-9. [Abstract]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Knox, J., Krzyzanowska, M., Oza, A., Feld, R., Hedley, D., Xu, W., Tattersall, M. (2011), Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(15), 2077-84. [Abstract]
  • Kiely, B., Wilcken, N., Stockler, M. (2011), Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29, 1092-1093. [Abstract]
  • de Boer, R., Chan, A., Tran, B., Wilcken, N. (2011), Use of non-anthracycline regimens in early stage breast cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 7(1), 4-10. [Abstract]

2010

   
  • Dickersin, K., Tovey, D., Wilcken, N., Ghersi, D. (2010), The background review for the USPSTF recommendation on screening for breast cancer. Annals of Internal Medicine. , 537; author reply 538-9. [Abstract]
  • Butters, D., Ghersi, D., Wilcken, N., Kirk, S., Mallon, P. (2010), Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews. 11(1), CD003368. [Abstract]
  • Dear, R., Tattersall, M., McGeechan, K., Barratt, A., Wilcken, N. (2010), Combination versus sequential single agent chemotherapy for metastatic breast cancer (Protocol). Cochrane Database of Systematic Reviews. 0(10), CD008792.

2009

   
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., K√∂stler, W., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C., Zwierzina, H. (2009), Third consensus on medical treatment of metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 20(11), 1771-85. [Abstract]
  • Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009), Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials. Breast. 18(3), 143-149. [Abstract]
  • Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009), Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane database of systematic reviews (Online). 0(4), CD000563. [Abstract]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., Wilcken, N. (2009), Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane database of systematic reviews. 0(2), CD003372. [Abstract]
  • Snyder, R., Boyle, F., Chan, A., Craft, P., De Boer, R., Mainwaring, P., McCarthy, N., Wilcken, N. (2009), Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. Asia-Pacific Journal of Clinical Oncology. 5(1), 4-16. [Abstract]

2008

   
  • Wilcken, N., Dear, R. (2008), Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. European Journal of Cancer. 44(15), 2218-2225. [Abstract]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008), Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling. 72(2), 239-245. [Abstract]
  • Dear, R., Wilcken, N., Shannon, J. (2008), Beyond chemotherapy--demystifying the new 'targeted' cancer treatments. Australian Family Physician. 37(1-2), 45-49. [Abstract]